Search bioRxiv⌕ Search

Biology subjects

Rubin, N.

Publications and source records attributed to Rubin, N..

3 recordsLinked to original sources

Neural competition and probabilistic representations

Perception and action show tight links to the statistical structure of physical stimuli and likely rewards, but the underlying mechanisms are unknown. A simple, biologically plausible network model shows that probabilistic behavior emerges naturally in diverse scenarios, and arises from sampling of competing responses. Notably, it also provides a principled computational rationale for the prevalent finding of balanced excitation and inhibition in the brain. Recurrent connections within a population of excitatory neurons embed multiple attractor states, and coupling to a pool of inhibitory neurons enforces mutual exclusivity among the states. Upon concurrent stimulation, competing attractors alternate in activity. These global state transitions are caused by local, uncorrelated spiking noise and yet convey, over time, the relative strengths of attractors' support. The simplest probabilistic competitive recurrent networks (PCRNs) allow for closed-form analysis, shedding light on the neural basis of choice behavior under uncertainty. More complex systems of laterally connected PCRNs can collectively resolve the myriad local ambiguities pervasive in sensory stimuli, rapidly settling into globally-consistent configurations that match perceptual reports. Alternations are crucial in all cases, and occur only if a PCRN's inhibitory pool is strong enough to prevent attractors' activity from reaching saturation. A balance between excitation and inhibition is thus both a prerequisite and a hallmark of probabilistic sampling in cortical networks.

neuroscience↗

Transient signaling of free ADP-ribose monitored with an intracellular biosensor

We have developed a biosensor enabling the dynamic, compartmentalized, and longitudinal measurements of intracellular ADP-ribose (ADPR) in live cells. Free ADPR is a critical signaling metabolite derived from nicotinamide adenine dinucleotide (NAD+). As an agonist for Transient Receptor Potential Melastatin 2 (TRPM2), ADPR levels can regulate immune responses during infection, as well as nociception and adjustment of core body temperature. The study of ADPR signaling has been limited, however, by a lack of methods to measure this metabolite in situ. Using the biosensor and its paired non-responsive control, we determine that intracellular ADPR accumulation was transient and tunable. We found that basal concentrations were in the nanomolar range and could be stimulated [~]30-fold to activate TRPM2. We identified that TRPM2 activation, measured by calcium influx, required an intracellular ADPR threshold concentration between 2 - 4 {micro}M at physiological temperature. We observed that the timing of the ADPR rise coincided with TRPM2 activation, thus providing support for ADPR fluctuations being a critically regulated aspect for channel activation. Notably, transient fluctuations of ADPR were not accurately reflected by measurements of intracellular NAD+ loss or calcium levels. Significance StatementWe have developed a unique real-time biosensor for free ADP-ribose that is tuned to physiological concentrations and capable of intracellular measurements in individual cells. Using a calibrated system we determined that concentrations and timing of induced intracellular ADPR aligned with the thermosensitive TRPM2 activity. The data support ADPR as a critical component whose intracellular levels are regulated to control TRPM2 channel opening in cells.

biochemistry↗

GLS1 is a Protective Factor Rather than a Molecular Target in ARID1A-Mutated Ovarian Clear Cell Carcinoma

Targeting glutamine metabolism has emerged as a novel therapeutic strategy for several human cancers, including ovarian cancer. The primary target of this approach is the kidney isoform of glutaminase, glutaminase 1 (GLS1), a key enzyme in glutamine metabolism that is overexpressed in several human cancers. A first-in-class inhibitor of GLS1, called CB839 (Telaglenastat), has been investigated in several clinical trials, with promising results. The first clinical trial of CB839 in platinum-resistant ovarian cancer patients is forthcoming. ARID1A-mutated ovarian clear cell carcinoma (OCCC) is a relatively indolent and chemoresistant ovarian cancer histotype. In OCCC-derived cells in vitro and mouse models, loss of ARID1A leads to upregulation of GLS1. Thus, targeting of GLS1 with CB839 has been suggested as a targeted approach for OCCC patients with tumors harboring ARID1A-mutations. Here, we investigated whether GLS1 is differentially expressed between OCCC patients whose tumors are ARID1A positive and patients whose tumors are ARID1A negative. In clinical specimens of OCCC, we found that GLS1 overexpression was not correlated with ARID1A loss. In addition, GLS1 overexpression was associated with better clinical outcomes. Our findings suggest that GLS1 expression in OCCC may be a protective factor and that caution should be taken when considering the use of CB839 to treat OCCC patients.

cancer biology↗